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ABSTRACT

ARTICLE HISTORY

While changes in DNA methylation are known to occur early in breast carcinogenesis and the landscape
of breast tumour DNA methylation is profoundly altered compared with normal tissue, there have been
limited efforts to identify DNA methylation field cancerization effects in histologically normal breast
tissue adjacent to tumour. Matched tumour, histologically normal tissue of the ipsilateral breast (ipsilateral-normal), and histologically normal tissue of the contralateral breast (contralateral-normal) were
obtained from nine women undergoing bilateral mastectomy. Laser capture microdissection was used to
select epithelial cells from normal tissue, and neoplastic cells from tumour for genome-scale measures of
DNA methylation with the Illumina HumanMethylationEPIC array. We identified substantially more CpG
loci that were differentially methylated between contralateral-normal and tumour (63,271 CpG loci
q < 0.01), than between ipsilateral-normal and tumour (38,346 CpG loci q < 0.01). We identified
differential methylation in ipsilateral-normal relative to contralateral-normal tissue (9,562 CpG loci
p < 0.01). In this comparison, hypomethylated loci were significantly enriched for breast cancerrelevant transcription factor binding sites including those for ESR1, FoxA1, and GATA3 and hypermethylated loci were significantly enriched for CpG island shore regions. In addition, progression of shore
hypermethylation was observed in tumours compared to matched ipsilateral normal tissue, and these
alterations tracked to several well-established tumour suppressor genes. Our results indicate an epigenetic field effect in surrounding histologically normal tissue. This work offers an opportunity to focus
investigations of early DNA methylation alterations in breast carcinogenesis and potentially develop
epigenetic biomarkers of disease risk.
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Introduction
Breast cancer is the most diagnosed non-keratinocyte
cancer and is responsible for the second highest number of cancer-related deaths among women in the
United States, with over 40,000 women estimated to
die from breast cancer in 2019 in the United States
alone [1]. It has been shown that the breast methylome
varies greatly between histologically normal tissue and
tumour tissue [2], and such variation is related in part
to age, parity, and alcohol consumption, among other
factors [3,4]. Work assessing the methylome of ductal

carcinoma in situ (DCIS) has demonstrated that alterations to DNA methylation occur early in breast carcinogenesis [5,6]. Due to the invasive nature of sample
collection, molecular studies are conducted as
a comparison between tumour and histologically normal tissue adjacent to the tumour (subsequently
referred to as adjacent normal) tissue. However,
given that alterations to DNA methylation have been
identified at the early stages of breast carcinogenesis, it
is currently unknown whether adjacent normal tissue
is reflective of normal breast epithelium at the molecular level. This limitation may lead to an incomplete

CONTACT Kathleen F. Arcaro
karcaro@umass.edu
Department of Veterinary & Animal Sciences, University of Massachusetts, Life Science Laboratory
1 Room N529, 240 Thatcher Road, Amherst, MA 01003-9298, USA
*These authors contributed equally to this work.
Supplemental data for this article can be accessed here.
© 2020 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-ncnd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built
upon in any way.

1094

M. E. MUSE ET AL.

understanding of tumour development or an attenuation of the measured magnitude of epigenetic
differences.
If a field effect of the tumour on adjacent histologically normal tissue occurs in breast cancer, the use
of adjacent normal tissue as a referent sample in
molecular studies would inhibit our ability to identify
the earliest molecular alterations that occur in carcinogenesis. Therefore, assessment of possible field cancerization effects in breast cancer is critical to
informing our understanding of early carcinogenesis.
A recent study demonstrated evidence of alterations
to DNA methylation related to tumorigenesis in histologically normal tissue adjacent to breast tumours,
suggestive of a field cancerization effect in breast cancer
[7]. However, this study was conducted comparing
adjacent normal tissue in women with breast cancer
to normal breast tissue in women without breast cancer. While comparing cancer-free control tissue from
one set of study participants with adjacent normal
tissue from an independent set of participants provides
initial evidence of field cancerization effects, it may
obscure the extent to which DNA methylation profiles
reflect individual differences/exposures and thereby
modify the field effect profile. To our knowledge, no
study to-date has shown evidence of field effects in
breast cancer using subject-matched tumour tissue,
histologically normal tissue from the ipsilateral breast
(ipsilateral-normal), and histologically normal tissue
from the contralateral breast (contralateral-normal).
Furthermore, most prior research assessing alterations
to DNA methylation in breast tumours has leveraged
bulk tissue samples which may confound results due to
underlying differences in the cellular composition of
collected tissue. In the present study, we present evidence of field effects in breast cancer, using subjectmatched, laser capture microdissected tumour, ipsilateral-normal, and contralateral-normal samples from
nine women undergoing bilateral mastectomy.

Results
Global trends in DNA methylation suggest
differences between ipsilateral-normal and
contralateral-normal breast tissue

Unsupervised hierarchical clustering using mean
methylation beta values of the top 10,000 most variable
probes across the three tissue types showed clear

separation between tumour and normal (ipsilateral or
contralateral) tissue (Figure 1). Among the cluster of
normal tissue, some samples clustered by subject (subjects 4, 7, and 8; Table 1) while some samples appeared
to separate by the breast from which they were collected
(ipsilateral or contralateral). When assessing the methylation status of Alu and long interspersed nucleotide
element-1 (LINE-1) repetitive elements, there was
a statistically significant decrease in median Alu element
methylation in tumour relative to contralateral-normal
tissue (p = 0.03) while no statistically significant differences were observed in ipsilateral-normal tissue relative
to tumour or contralateral-normal tissue (Additional file
1: Figure S1). However, there was visual suggestion of
a trend in decreased Alu element methylation across
contralateral-normal, ipsilateral-normal, and tumour
tissue respectively. No statistically significant differences
were observed in the methylation status of LINE-1 elements across tissue types.

Contralateral-normal tissue provides a distinct
reference epigenome compared to
ipsilateral-normal tissue

At an FDR cut-off of q < 0.01, a total of 38,346 CpG loci
were identified as differentially methylated in tumour
tissue relative to ipsilateral-normal tissue (Figure 2(b)).
However, when comparing tumour tissue to contralateral-normal tissue, 63,271 CpG loci were identified as
differentially methylated (Figure 2(a)), a 65% increase.
Furthermore, among those differentially methylated loci,
33,657 (88% of those identified as differentially methylated using ipsilateral-normal as the referent tissue and
53% of those identified as differentially methylated using
contralateral-normal as there referent tissue) were identified in both comparisons (Figure 2(c)) with consistent
directionality of association in tumour relative to the
respective referent tissue.
In a sensitivity analysis removing the contralateral
normal-sample from the subject whose ipsilateralnormal sample was removed from analysis during
QC due to > 10% of probes being above the specified
detection p value (Subject 1) to allow for matched
sample size across comparisons, a modest decrease
was observed in the number of loci identified as differentially methylated (Additional file 2: Figure S2).
However, there remained a 23% increase in the number of differentially methylated loci observed relative to
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Figure 1. Heatmap with unsupervised hierarchical clustering based on Manhattan distance of tumour, ipsilateral-normal, and
contralateral-normal methylation profiles.
Table 1. Selected subject and tumour characteristics.
Subject
1
2
3
4
5
6
7
8
9

Age
47
66
61
42
52
49
46
50
32

Parity
2
4
2
2
2
2
4
0
1

Carcinoma
Invasive
Invasive
Invasive
In Situ
N/A
Invasive
Invasive
In Situ
Invasive

ER
+
+
+
+
N/A
+
+
+
+

PR
+
+
+
N/A
+
+
+
+

HER2
+
+
N/A
N/A
+
N/A
+

Size (cm)
1.4
0.2
2.5
N/A
N/A
2.1
2.5
N/A
5.1

Grade
2
3
3
N/A
N/A
2
1
N/A
3

Contralateral Normala
1
1
1
1
1
1
1
1
1

Ipsilateral Normala
0
1
1
1
1
1
1
1
1

Tumora
1
1
1
1
0
1
1
1
1

+ = positive; – = negative; N/A = not available; a Number of samples included in the analysis.

the comparison using ipsilateral-normal tissue as the
referent tissue.
To further assess whether the observed increase in
differentially methylated CpGs were functionally

redundant and reflected more loci from the same
genes being identified as differentially methylated, we
investigated the overlap in genes and gene sets. The
38,346 differentially methylated CpG loci identified
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Figure 2. Epigenome-wide association analyses identifying CpG sites that are significantly differentially methylated in (a) tumour
relative to contralateral-normal tissue and (b) tumour relative to ipsilateral-normal tissue. The beta coefficient reflects the difference
in M-value associated with tissue type, adjusted for subject age and parity. Red dashed lines indicate a significance threshold of
q < 0.01 and black dashed lines indicate a significance threshold of q < 0.05. CpGs are coloured (red) by sites identified as significant
in the tumour versus contralateral-normal tissue (q < 0.01) analysis. (c) Overlap (green) between significantly differentially
methylated CpG loci (q < 0.01) in tumour versus contralateral-normal and tumour versus ipsilateral-normal tissue. (d) Epigenomewide association analysis identifying CpG sites that are significantly differentially methylated in ipsilateral-normal relative to
contralateral-normal tissue. Red dashed lines indicate a significance threshold of p < 0.01 and black dashed lines indicate
a significance threshold of p < 0.05.

when comparing tumour to ipsilateral-normal tissue
mapped to 9,800 unique genes. Conversely, the 63,271
differentially methylated CpG loci identified when
using contralateral-normal as the referent tissue
mapped to 12,887 genes, 9,283 of which were overlapping with those identified in the tumour relative to
ipsilateral-normal comparison.

We used the gometh function from the
missMethyl package in R, which takes into account
the differing number of probes per gene present
on the EPIC array, to identify gene sets that were
enriched among the 29,614 differentially methylated CpG loci in tumour relative to contralateralnormal tissue that were not identified when using

EPIGENETICS

ipsilateral normal tissue as the referent tissue.
These 29,614 were compared to the background
set of all 63,271 differentially methylated loci identified between tumour and contralateral-normal
tissue to investigate GO terms that may be
uniquely implicated in early carcinogenesis. We
identified significant enrichment of (q < 0.01) 83
GO terms with the most significantly enriched GO
terms relating to biological processes such as cell
death, metabolic processes, and tissue development (Additional file 3: Table S1).
Hypomethylated loci in ipsilateral-normal
relative to contralateral-normal tissue are
enriched for transcription factor binding sites
implicated in breast carcinogenesis

In analyses comparing ipsilateral-normal to contralateral-normal tissue, 9,562 CpG loci were identified as differentially methylated between the two
histologically normal tissue types at a nominal significance threshold of p < 0.01 (Figure 2(d)). Given
differences in the biological interpretation of
hypomethylation and hypermethylation, respectively, subsequent analyses were stratified by the
direction of the identified association.
Among the 9,562 differentially methylated loci,
4,942 were identified as hypomethylated in ipsilateral-normal relative to contralateral-normal tissue
(Additional file 4: Table S2). These hypomethylated loci demonstrated significant enrichment
for CpG sparse open sea regions (OR = 1.77;
95% CI: 1.66, 1.88; p = 5.1 x 10−63) and significant
depletion for all other CpG island associated genomic contexts (Figure 3(a)).
To further explore possible regulatory roles of
differentially methylated CpG loci in ipsilateralnormal relative to contralateral-normal tissue we
next assessed enrichment for transcription factor
binding sites (TFBSs), using the Locus Overlap
Analysis (LOLA) software tool. Using the LOLA
core database for hg19, we assessed enrichment for
these loci at TFBSs using Cistrome data for the
breast cancer cell lines MCF-7 and T47D.
Comparing the identified hypomethylated loci
(p < 0.01) in ipsilateral-normal relative to contralateral-normal tissue to the background set of all
683,209 loci included in our epigenome-wide association study, we identified statistically significant
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enrichment of TFBSs for c-Fos, ESR1, FoxA1,
GATA3, RAD21, RARA, RARG, and SRC-3
using MCF-7 data and ESR1, FoxA1, and PGR
using T47D data (all q < 0.05, Figure 4). This
suggests that cellular programmes regulated by
transcription factors known to be dysregulated in
invasive breast cancer also contribute to early
events in breast carcinogenesis.
Hypermethylated loci in ipsilateral-normal
relative to contralateral-normal tissue are
depleted for CpG islands but enriched for
adjacent shore regions

4,620 loci were identified as hypermethylated in
ipsilateral-normal relative to contralateral-normal
tissue (Additional file 5: Table S3). Using the
LOLA core database for hg19, no statistically significant enrichments for TFBSs were identified
among the hypermethylated loci in ipsilateralnormal relative to contralateral-normal tissue.
However, these 4,620 loci demonstrated modest
enrichment for open sea regions (OR = 1.06; 95%
CI: 1.00, 1.13, p = 0.044), significant depletion for
CpG island regions (OR = 0.65; 95% CI: 0.59, 0.71,
p = 6.8 x 10−20), and significant enrichment for
CpG island shore regions (north shores OR = 1.13;
95% CI: 1.03, 1.23; p = 0.010 and south shores
OR = 1.21; 95% CI: 1.11, 1.33; p = 5.7 x 10−5;
Figure 3(b)). As not all CpG islands track to promoter regions, we restricted our enrichment analyses to CpG islands in gene promoter regions
which demonstrated further depletion for CpG
island regions (OR = 0.58; 95% CI: 0.52, 0.66;
p = 8.2 x 10−18) and further enrichment for CpG
island south shore regions (OR = 1.29; 95% CI:
1.14, 1.45, p = 4.8 x 10−5; Figure 3(b)), among
CpGs hypermethylated in ipsilateral relative to
contralateral normal tissue. Importantly, when
assessing the genomic context distribution among
the 71,407 hypermethylated loci in tumour relative
to contralateral-normal tissue (p < 0.01), we
observed strong enrichment for both CpG shore
regions (north shore OR = 1.34; 95% CI: 1.31, 1.37;
1.7 x 10−110, south shore OR = 1.31; 95% CI: 1.28,
1.35, p = 5.2 x 10−85; Figure 3(c)), and CpG islands
(OR = 1.52; 95% CI: 1.49, 1.55; p = 1.9 x 10−319).
These data provide evidence that the earliest
alterations to DNA methylation occur in the
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Figure 3. (a) Enrichment/depletion of CpG island contexts from a Cochran-Mantel-Haenszel test comparing identified CpG loci to all
other CpG loci included in the analysis, adjusting for Illumina probe type (a) among the 4,942 CpG loci found to be significantly
(p < 0.01) hypomethylated in ipsilateral-normal relative to contralateral-normal tissue, (b) among the 4,620 CpG loci found to be
significantly (p < 0.01) hypermethylated in ipsilateral-normal relative to contralateral-normal tissue as well as the subset of 1,421
hypermethylated loci annotated to gene promoter regions, (c) among the 71,407CpG loci found to be significantly (p < 0.01)
hypermethylated in tumour relative to contralateral-normal tissue as well as the subset of 30,455 hypermethylated loci annotated to
gene promoter regions.
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Figure 4. Enrichment of transcription factor binding sites in MCF-7 and T47D cell lines as assessed in LOLA using Cistrome data
among the 4,942 CpG loci found to be significantly (p < 0.01) hypomethylated in ipsilateral-normal relative to contralateral-normal
tissue.

shore regions bordering CpG islands and that
altered DNA methylation spreads to the island
regions during tumorigenesis.
To more explicitly investigate progression of hypermethylation in tumours, we compared tumour DNA
methylation data to ipsilateral normal tissue in our
matched samples. Among the 4,620 hypermethylated
loci in ipsilateral relative to contralateral normal tissue,
24.2% (n CpGs = 1,118), had increased methylation in
tumour relative to ipsilateral normal. Of the 978
hypermethylated loci in ipsilateral relative to contralateral normal that tracked in CpG island shore
regions, 32.3% (n CpGs = 316), had increased methylation in tumour relative to ipsilateral normal tissue.
Among these 316 shore loci we selected the top 20
most statistically significant hypermethylated shore
CpG loci in tumour relative to ipsilateral normal and
investigated the potential for spreading of hypermethylation from the shore to neighbouring CpG
island loci (Additional file 6: Table S4). We plotted

the distribution of methylation at interrogated loci
mapping to the CpG island shore of interest and the
adjacent CpG island at each of these loci (Figure 5,
Additional file 7). For previously documented tumour
suppressor genes FAAP20, SST, and VGLL4, hypermethylation can be observed spreading across the
shore region in all genes as well as into the associated
promoter CpG island for SST and VGLL4 in tumour
tissue (Figure 5).
Discussion
Our findings suggest that within the same patient,
histologically normal breast tissue from the same
breast as a tumour is epigenetically distinct from
histologically normal tissue from the opposite
breast. Furthermore, histologically normal tissue
collected from the breast without the tumour
appears to be more epigenetically distinct from
tumour tissue than histologically normal tissue
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Figure 5. Distribution of the methylation status at interrogated CpG loci in the promoter CpG island and surrounding CpG island
shores across contralateral normal, ipsilateral normal, and tumour tissue for (a) FAAP20 (b) SST and (c) VGLL4.

collected from the same breast as the tumour. This
is suggestive of a field cancerization effect of the
tumour on surrounding histologically normal

tissue. These findings are consistent with previous
work that demonstrated differential variance of
DNA methylation in histologically normal tissue

EPIGENETICS

adjacent to a breast tumour relative to normal
breast tissue from cancer-free women [7] as an
increase in the variability of DNA methylation profiles in so-called ‘adjacent normal’ tissue would
decrease the power to identify differences in DNA
methylation relative to tumour. While our study is
limited by sample size, it presents a unique and
valuable resource due to the paired nature of our
samples.
While differences between ipsilateral-normal and
contralateral-normal tissue were modest and did not
achieve statistical significance at an FDR threshold of
q < 0.05, differentially methylated CpG loci at a nominal significance threshold of p < 0.01 were significantly enriched for regions of functional significance
including CpG island shore regions and tissue specific
regulatory regions. This suggests that these differences
may have important implications for the regulation of
gene expression between the two tissue types.
Furthermore, enrichment of CpG island shore
regions but depletion of CpG island regions
among hypermethylated loci in ipsilateral-normal
relative to contralateral-normal tissue, with greater
magnitudes of enrichment and depletion observed
when restricting to gene promoter regions, suggests that the earliest molecular alterations in carcinogenesis might appear as hypermethylation of
CpG island shore regions and that these early
alterations may also be present in histologically
normal tissue surrounding the tumour. These
findings are further supported by existing work
demonstrating methylation encroachment at the
borders of CpG islands in breast cancer and prostate cancer cells [8], suggesting that hypermethylation of promoter regions over the course of
carcinogenesis might begin at CpG island shores
and progress into the islands.
Inspection of the promoter CpG island shore
methylation profile for genes FAAP20, SST, and
VGLL4, showed that while there was hypermethylation of a single shore locus in ipsilateral relative to
contralateral normal tissue, hypermethylation
spread in tumour tissue was consistently observed
across the shore and, for SST and VGLL4, into the
island itself. This finding lends additional support
for the hypothesis that initial seeding events for the
widely observed hypermethylation of promoter CpG
islands in tumour tissue occur in the bordering shore
regions [8]. Furthermore, the hypermethylation of
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promoter CpG islands for the interrogated genes
have important functional implications for breast
carcinogenesis. FAAP20 plays an important role in
DNA repair via the Fanconi anaemia-BRCA pathway [9] and prior work has suggested that epigenetic
alterations to genes in this pathway may play a role in
the development of cervical cancer [10] and ovarian
cancer [11]. SST is a neuropeptide that has been
shown in models of breast cancer to both inhibit
growth factors and hormones known to promote
tumour growth, as well as prevent receptor signalling
that can trigger apoptosis [12]. Additionally, the role
of epigenetic silencing as a means of suppressing SST
expression in tumour cells has previously been suggested by the observed hypermethylation of the SST
promoter CpG island in multiple tumour types
including cervical cancer [13], colorectal cancer
[14,15], gastric cancer [16], and renal cell carcinoma
[17]. VGLL4 has also been identified as a potential
tumour suppressor gene across multiple tumour
types including breast cancer [18], gastric cancer
[19], and lung cancer [20] and overexpression of
VGLL4 has been found to suppress breast tumour
growth in vivo [18]. Therefore, the potential for
suppression of VGLL4 expression through promoter
hypermethylation could contribute to breast
carcinogenesis.
Histologically normal tissue in the breast harbouring tumour also shows evidence of early molecular
alterations that may be implicated in carcinogenesis
among loci that are hypomethylated in this tissue
relative to contralateral-normal tissue. These loci
demonstrate enrichment for binding sites for transcription factors previously implicated in breast cancer, suggesting that hypomethylation of these loci may
play a role in transcriptional regulation. It is also
important to note that the cross-sectional nature of
the study design precludes us from assessing the temporality of these alterations. Therefore, it is also possible that molecular alterations observed in ipsilateralnormal relative to contralateral-normal tissue reflect
paracrine effects of the tumour on surrounding tissue
[21,22] rather than precursor events to tumorigenesis.
However, loci that demonstrate a directionally consistent association between both tumour and ipsilateral normal tissue relative to contralateral normal
tissue, as well as CpG islands demonstrating spreading from shore hypermethylation in ipsilateral normal
to island hypermethylation in tumour tissue relative
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to contralateral normal tissue suggest progression of
local DNA methylation alterations in carcinogenesis.
Prior work assessing the DNA methylation profiles of
pre-invasive ductal carcinoma in situ lesions has also
demonstrated that alterations to DNA methylation
occur early on in breast carcinogenesis [5].
Nonetheless, the observed differences in the epigenetic profile of ipsilateral-normal and contralateralnormal tissue suggest that histologically normal tissue
collected from the affected breast is an imperfect
referent tissue for the tumour.
We did not identify significant differences
between the methylation status of Alu and LINE1 repetitive elements across tissue types. While
previous work has identified hypomethylation of
these repetitive elements over the course of carcinogenesis [23], these findings were subtypespecific. Therefore, given our limited sample size,
it is unclear whether such associations might be
observed given the lack of power to stratify analyses by molecular subtype.
Observed differences have important implications for molecular research in which histologically normal tissue adjacent to a tumour is used
as a comparison group when evaluating for molecular alterations in tumour tissue. Given that our
study collected ipsilateral-normal tissue at
a distance of 3 cm from the tumour, 1 cm more
distal from the tumour than the TCGA specified
2 cm minimum distance for the collection of adjacent normal tissue, this is suggestive that adjacent
normal tissue may not be an adequate referent
tissue. The observed effect of the tumour/tumour
microenvironment on adjacent normal tissue may
attenuate results when adjacent normal tissue is
used as a comparison. In such cases, research may
fail to identify significant differences at certain loci
between tumour tissue and benign breast tissue
within the same individual due to an unquantified
field cancerization effect on the referent tissue. In
addition, these loci may reflect the earliest alterations to DNA methylation in breast carcinogenesis
and, therefore, failing to identify alterations at
these loci may limit our understanding of early
carcinogenesis. Our findings suggest that additional research is needed to identify molecular
differences between breast tumours and normal
breast tissue that previous research utilizing histologically normal adjacent tissue may have been

unable to capture. While outside of the scope of
the present work, extending the present findings to
histologically normal breast tissue from women
without breast cancer and histologically normal
tissue adjacent to breast tumours could further
elucidate our understanding of how DNA methylation mediates the association between known
breast cancer risk factors and subsequent breast
cancer development, building upon the existing
body of literature in this space [7,24].
Our results indicate that histologically normal
tissue collected from the same breast as the
tumour harbours field cancerization effects and is
not an ideal referent tissue for identifying breast
tumour DNA methylation alterations, particularly
early events in carcinogenesis. Our results also
suggest that early hypermethylation events in
breast carcinogenesis are more likely to occur in
the regions immediately surrounding CpG islands
than within CpG islands. This work offers an
opportunity to focus investigations of early DNA
methylation alterations in breast carcinogenesis
and potentially develop epigenetic biomarkers of
disease risk.
Methods
Study population

This was a retrospective study using formalinfixed, paraffin-embedded (FFPE) archival tissue
blocks from treatment-naïve women who had
undergone elective bilateral mastectomies (tumour
mastectomy and prophylactic contralateral mastectomy) due to patient choice for aggressive therapy at Baystate Medical Center, Springfield, MA
and who were enrolled in the Rays of Hope Center
for Breast Research Registry (IRB Baystate Health,
Springfield, MA protocol number 568088).

Laser-capture microdissection and DNA isolation

Breast tumour, ipsilateral-normal, and contralateral-normal tissue blocks were identified and
pulled for each of 9 women. H&E stained sections
of the tumour and benign samples were used to
estimate the total area for microdissection;
a minimum of 5 × 106 μm2 was required to ensure
sufficient material for adequate DNA yield (~800
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ng minimum). There was insufficient tumour tissue available for one woman. Consecutive tissue
sections (6-μm thick) were cut and mounted on
membrane slides (MMI, Rockledge, FL). For
tumour blocks, every 4th section was H&E stained
and the tumour tissue was marked by a breast
pathologist (GMC). For ipsilateral-normal samples, benign glandular areas were selected from
blocks that were at least 3 cm from the tumour
tissue. For contralateral-normal samples, benign
glandular areas were selected. For both ipsilateral
and contralateral samples, glandular tissue was
marked on an H&E slide by a pathologist
(GMC). For each sample the 6-μm sections
mounted on membrane slides were deparaffinized
in 3 changes of Xylene and allowed to air dry
under vacuum in a desiccator for 30 min prior to
the laser-capture microdissection. The unstained
sections were oriented for microdissection aided
by landmarks defined on the H&E stained slides.
Areas to be microdissected were circumscribed
using MMI Cell Tools software (Version
Celltools-4.4 #261, Rockledge FL). Microdissected
tumour, ipsilateral-normal, and contralateralnormal samples from each patient were collected
separately onto caps. The collected tissue was
placed in 150 μL digestion buffer containing
10 μL proteinase K, kept overnight at 55°C, and
stored at −80°C until further processing. DNA was
isolated using the manufacturer’s protocol for the
BiOstic DNA FFPE Tissue Kit (MoBio).
DNA methylation profiling

DNA samples were sent to the Molecular Genomics/
Methylation Core at the University of Southern
California. Bisulphite treatment with the EZ DNA
methylation kit (Zymo) was performed and bisulphite-converted DNA was processed as described in
the Infinium FFPE Restoration guide (Illumina, San
Diego, CA, USA). Modified DNA was assessed with
four PCR reactions to estimate quantity and test for
complete bisulphite conversion [25]. DNA samples
that passed the PCR quality controls were amplified
at 37°C for 20–24 hours after treatment with 0.1 N
NaOH. The DNA was fragmented at 37°C for 1 hour
and subsequently precipitated in 100% 2-propanol at
4°C for 30 minutes followed by centrifugation at
3000xg at 4°C for 20 minutes. Dried DNA-pellets
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were resuspended in hybridization buffer at 48°C for
1 hour, denatured for 20 minutes at 95°C and loaded
onto the Human MethylationEPIC BeadChip, and
hybridized at 48°C for 16–24 hours. Unhybridized
and non-specific DNA was removed using wash
buffers. After a single base extension of the hybridized primers using labelled nucleotides, the
BeadChip was stained with Cy-3 and Cy-5 fluorescent dyes and read using the Illumina iScan Reader.
DNA methylation data processing

Sample intensity data (IDAT) files were processed
with the R package minfi using the ‘Funnorm’ normalization method on the full dataset. CpGs with
a detection p value > 1E-06 in more than 5% of samples, CpGs with high frequency SNP(s) in the probe,
probes previously described to be potentially crosshybridizing, and sex-specific probes were filtered.
Samples with more than 10% of probes above the
detection p value or with bisulphite conversion intensity less than 3 standard deviations of the mean were
removed.
One ipsilateral-normal sample was removed due to
poor sample quality (>10% of probes above the detection p value). From an original set of 853,307 measured
CpG
loci
on
the
Illumina
HumanMethylationEPIC array (EPIC), our filtering
steps removed 96,564 probes exceeding the detection
p value limit, 71,478 probes that were SNP associated
or cross-hybridizing, and 15,585 sex-specific probes.
The final data for analysis resulted in 683,209 CpG loci
measured in 25 matched samples from nine women
(Table 1) from tumour tissue (n = 8), ipsilateralnormal tissue (n = 8), and contralateral-normal tissue
(n = 9).
Statistical analysis

Unsupervised hierarchical clustering was conducted
based on Manhattan distance and using the 10,000
CpG loci that demonstrated the most variability in
methylation beta value across all samples.
To quantify differential methylation, pairwise comparisons were run on logit-transformed methylation
beta values (M-values) between contralateral-normal
and tumour tissue, ipsilateral-normal and tumour
tissue, and contralateral-normal and ipsilateralnormal tissue. Linear mixed-effect models were
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performed to model the relation between tissue type
(tumour relative to contralateral-normal, tumour
relative to ipsilateral-normal, and ipsilateral-normal
relative to contralateral-normal, respectively) and
CpG methylation M-value, controlling for age and
parity and allowing a random effect for each subject.
Due to the limited sample size of the study, we utilized
nominal significance levels of p < 0.01 for subsequent
analyses and interpretations.
To classify the genomic context of identified differentially methylated CpG loci, annotation data for the
Illumina HumanMethylationEPIC array was used to
identify the relation to CpG islands for each probe.
The UCSC Genome Browser UCSC_hg19_refGene
file was used to define promoters, exons, introns,
and intergenic regions and the R package
GenomicRanges was used to map these regions to all
CpG loci on the Illumina HumanMethylationEPIC
array. In cases where CpG loci mapped to more than
one genomic region, loci were preferentially assigned
to promoters, then exons, and then introns such that
each locus only had one associated genomic region.
Gene set enrichment analyses of identified differentially methylated CpG loci were conducted
using the gometh function from the missMethyl
package in R [26]. In brief, this method assesses
enrichment of represented gene ontology (GO)
terms among a set of differentially methylated
CpG loci relative to a specified background set
while adjusting for potential bias introduced by
differences in the number of probes that map to
each gene leading to altered probability of identifying a differentially methylated locus across different genes.
Cochran-Mantel-Haenszel tests were used to calculate odds ratios (ORs) and p values for the enrichment
of CpG island contexts, adjusting for Illumina probe
type, among CpG loci that were significantly hypomethylated or hypermethylated (p < 0.01) in ipsilateral-normal relative to contralateral-normal tissue,
compared to all other CpG loci included in the
analysis.
To assess possible enrichment of regulatory elements among hypomethylated and hypermethylated (p < 0.01) loci, respectively, in ipsilateralnormal relative to contralateral-normal tissue, we
utilized Locus Overlap Analysis (LOLA) [27] using
Cistrome data for MCF-7 and T47D breast cancer
cell lines from the LOLA core database for hg19. In

brief, LOLA conducts a Fisher’s Exact Test for the
enrichment of the identified differentially methylated loci relative to a specified background set
(here specified as the 683,209 loci included in the
analysis) overlapping with specified regulatory
elements.
Methylation status of Alu and long interspersed
nucleotide element-1 (LINE-1) repetitive elements
were predicted using the REMP package in R [28].
Median value of Alu and LINE-1 were subsequently calculated across all reported regions for
each sample. Median Alu and LINE-1 methylation
status was then compared between tissue types
using a Wilcoxon rank-sum test.
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